Drugs / V132 Formulation 1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07712575 | Aug 2026 → Jun 2028 expected | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V132 Formulation 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07712575 ↗ |
| Modality | Vaccine | “the V132 vaccine” NCT07712575 ↗ |
| Route | Intramuscular | “single intramuscular (IM) doses” NCT07712575 ↗ |